The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Perioperative epirubicin, oxaliplatin, and capectabine (EOX) in locally advanced resectable gastroesophageal junction and gastric adenocarcinoma.
Roshni Deepa Kalachand
No relevant relationships to disclose
Anne-Marie Mongan
No relevant relationships to disclose
Mark Doherty
No relevant relationships to disclose
Sinead King
No relevant relationships to disclose
Niamh O'Farrell
No relevant relationships to disclose
John Vincent Reynolds
No relevant relationships to disclose
Kenneth John O'Byrne
No relevant relationships to disclose